by A team of researchers led by the National Institutes of Health (NIH), specifically the National Eye Institute (NEI), has delved deeper into the intricate molecular mechanisms underlying neurodegenerative disorders linked to the gene PNPLA6. These conditions span a spectrum of symptoms, including vision impairment, mobility issues, and hormonal dysregulation.
The team’s findings, published in the journal Brain, provide valuable insights into PNPLA6-related disorders at the clinical, genetic, and molecular levels. This new understanding opens doors for the development of targeted diagnostic and therapeutic strategies.
The root cause of PNPLA6-related disorders lies in mutations that disrupt the function of an enzyme called neuropathy target esterase (NTE), which plays a crucial role in neurons’ lipid metabolism and membrane stability. Impaired NTE activity has been implicated in neurological disorders such as organophosphate-induced delayed neuropathy, hereditary spastic paraplegia, Boucher-Neuhäuser syndrome, and Oliver-McFarlane syndrome.
To gain a comprehensive understanding of these conditions, Robert Hufnagel, M.D., Ph.D., and colleagues at the NEI conducted an extensive review and analysis of data from over 100 patients with PNPLA6 mutations. Utilizing neuroimaging, electrophysiological studies, and genetic testing information, the researchers meticulously assessed patients’ mobility, vision, and hormone expression.
